Rosuvastatin . calcium salt

CHF 30.00
In stock
AG-CR1-3728-M01010 mgCHF 30.00
AG-CR1-3728-M05050 mgCHF 60.00
AG-CR1-3728-M250250 mgCHF 220.00
More Information
Product Details
Synonyms Crestor
Product Type Chemical
Properties
Formula

C22H27FN3O6S . 1/2Ca

MW 480.6 . 20.0
CAS 147098-20-2
RTECS MJ9675070
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (20mg/ml) or DMF (20mg/ml).
Identity Determined by 1H-NMR.
InChi Key VGAZDTHGPVFCCO-YFRSHGDPSA-K
Smiles CN(S(C)(=O)=O)C1=NC(C2=CC=C(F)C=C2)=C(/C=C/[C@H](C[C@@H](O)CC([O-])=O)O)C(C(C)C)=N1.[Ca+2]
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Rosuvastatin is a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the statin class of cholesterol-lowering drugs.
  • Rosuvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.
  • Shown to have anti-inflammatory, antioxidant, antithrombotic and insulin sensitizing properties.
  • Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
Product References
  1. Structural mechanism for statin inhibition of HMG-CoA reductase: E.S. Istvan & J. Deisenhofer; Science 292, 1160 (2001)
  2. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: F. McTaggart, et al.; Am. J. Cardiol. 87, 28B (2001)
  3. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor: A.G. Olsson, et al.; Cardiovasc. Drug Rev. 20, 303 (2002) (Review)
  4. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors: J.A. Tobert; Nat. Rev. Drug Discov. 2, 517 (2003) (Review)
  5. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia: A. Cheng-Lai; Heart Dis. 5, 72 (2003) (Review)
  6. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin: G.A. Holdgate, et al.; Biochem. Soc. Trans. 31, 528 (2003) (Review)
  7. Rosuvastatin: a review of its effect on atherosclerosis: G.M. Keating & D.M. Robinson; Am. J. Cardiovasc. Drugs. 8, 127 (2008) (Review)
  8. Rosuvastatin: Beyond the cholesterol-lowering effect: F. Cortese, et al.; Pharmacol. Res. 107, 1 (2016) (Review)
  9. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning: P. Wang, et al.; ChemRxiv (Preprint) (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.